ScienceFDA approves Lilly’s once-weekly insulin for adults with type 2 diabetes
The treatment, called Onswik, offers an alternative to daily long-acting insulin injections, STAT reports.
TLDR
STAT reports that the FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes. The outlet cites Lilly’s estimate that weekly dosing could eliminate more than 300 injections a year.
FDA approves Lilly’s once-weekly insulin for adults with type 2 diabetes
The treatment, called Onswik, offers an alternative to daily long-acting insulin injections, STAT reports.
TLDR
STAT reports that the FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes. The outlet cites Lilly’s estimate that weekly dosing could eliminate more than 300 injections a year.